NEW YORK (GenomeWeb) – Contextual Genomics and the Personalized Medicine Initiative today announced that Pfizer Canada has joined the National Access Project for Cancer Testing.
Pfizer Canada has provided a grant of an undisclosed amount and technical support as part of its commitment to the consortium, whose goal is to provide genomic testing to all Canadians diagnosed with cancer and to accelerate a personalized approach to treating the disease.
The National Access Project launched in February and is managed by the Personalized Medicine Initiative. Contextual Genomics provides a 90-mutation cancer genomics test for 2,000 Canadian cancer patients, free of charge, as part of the project. Each mutation that is identified is treated with current medications or Phase III investigational treatments.
In February, drug maker AstraZeneca joined the consortium.